Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508741 | 1.00 | MDM2 (0.36) | MDM2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1508739 | 0.88 | KCNQ3 (0.34) | MDM2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1508742 | 0.88 | KCNQ3 (0.34) | MDM2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1508874 | 0.87 | KCNQ3 (0.39) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14817144 | 0.86 | ABCC9 (0.35) | MDM2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL1508733 | 0.86 | KMO (0.32) | — | |
| SCHEMBL14793575 | 0.83 | KMT2A (0.33) | MDM2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14817142 | 0.83 | KMT2A (0.33) | MDM2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1509045 | 0.83 | KCNQ3 (0.31) | KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1508909 | 0.78 | KCNQ3 (0.37) | MDM2KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| WO-2010082612-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | MDM2, TP53, TP53BP1 | MDM2 1/4885KCNQ3 4864/4885KCNQ2 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.